Lymphadenopathy screening: Difference between revisions
Jump to navigation
Jump to search
m (Bot: Removing from Primary care) |
No edit summary |
||
Line 2: | Line 2: | ||
{{Lymphadenopathy}} | {{Lymphadenopathy}} | ||
{{CMG}}; {{AE}} {{ADS}} | {{CMG}}; {{AE}} {{ADS}} [[Ogechukwu Hannah Nnabude, MD]] | ||
==Overview== | ==Overview== | ||
Latest revision as of 05:17, 9 December 2021
Lymphadenopathy Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Lymphadenopathy screening On the Web |
American Roentgen Ray Society Images of Lymphadenopathy screening |
Risk calculators and risk factors for Lymphadenopathy screening |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Amandeep Singh M.D.[2] Ogechukwu Hannah Nnabude, MD
Overview
There is insufficient evidence to recommend routine screening for lymphadenopathy
Screening
- There is insufficient evidence to recommend routine screening for lymphadenopathy